ALERT:

Clinical Trial

Lung Cancer Clinical Trial 20203206

[LCID Study Number: 20203206]

EA5182, Randomized Phase III Study of Combination AZD9291 (Osimertinib) and Bevacizumab Versus AZD9291 (Osimertinib) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)

The purpose of this study is to compare a combination of two study drugs versus a single drug in treating non-small cell lung cancer.

Disease/Condition: Lung Cancer

Department: Hematology and Oncology

Location(s): Lahey Hospital & Medical Center (Burlington); Lahey Medical Center, Peabody

Primary Contact Email: cancerclinicaltrials@lahey.org

Primary Contact Phone: 781-744-3421

Clinical Trial Details

View NCT ID 04181060 on ClinicalTrials.gov

Protocol #: 20203206

Principal Investigator(s): Paul Hesketh, MD

Trial Phase: Sponsor Initiated Study Phase 3